Crossmark

Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

Crossref DOI link: https://doi.org/10.1038/s41408-026-01510-1

Published Online: 2026-04-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gustine, Joshua N. https://orcid.org/0009-0008-8300-1266
Attar, Narsis

Puliafito, Benjamin R.

Cirstea, Diana D.

Branagan, Andrew R. https://orcid.org/0000-0002-3868-9267
Yee, Andrew J. https://orcid.org/0000-0003-3623-7491
Raje, Noopur S. https://orcid.org/0000-0003-3066-1275
License Information

Text and Data Mining valid from 2026-04-22

Accepted Manuscript valid from 2026-04-22
More Information

Article History

Received: 19 October 2025

Revised: 8 March 2026

Accepted: 14 April 2026

First Online: 22 April 2026

Competing interests

: AJY has been a consultant for AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Johnson & Johnson (Janssen), Karyopharm, Oncopeptides, Pfizer, Prothena, Regeneron, Sanofi, Sebia, Takeda, and has received research funding to the institution from Amgen, BMS, GSK, Johnson & Johnson (Janssen), and Sanofi. NSR has been a consultant for AbbVie, Amgen, BMS, Janssen, Pfizer, Immuneel, GSK, K36 Therapeutics, Sanofi, Roche, Caribou Biosciences, Kelonia Therapeutics, and AstraZeneca, and has received research funding to the institution from Pfizer. The remaining authors have no competing interests to disclose.

: This study was approved by the Institutional Review Board of Massachusetts General Hospital (15-190). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations. Informed consent was obtained from all individual participants in this analysis.

Document is current

Any future updates will be listed below